# Safety, Reactogenicity and Immunogenicity of an H5N1 VLP

> **NCT00519389** · PHASE1,PHASE2 · COMPLETED · sponsor: **Novavax** · enrollment: 230 (actual)

## Conditions studied

- Pandemic Influenza

## Interventions

- **BIOLOGICAL:** H5N1 VLP Vaccine
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT00519389
- **Lead sponsor:** Novavax
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-07
- **Primary completion:** 2008-11
- **Final completion:** 2008-11
- **Target enrollment:** 230 (ACTUAL)
- **Last updated:** 2013-06-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00519389

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00519389, "Safety, Reactogenicity and Immunogenicity of an H5N1 VLP". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00519389. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*